Text and Data Mining valid from 2018-08-22
Received: 27 March 2018
Accepted: 23 April 2018
First Online: 22 August 2018
Duality of interest
: SV reports receiving research grants and/or speaking honoraria from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb-Pfizer, Eli Lilly, Janssen, Merck, Novartis, Novo Nordisk, Sanofi and Valeant. JJVM reports that his employer, the University of Glasgow, paid for his participation in clinical trial committees by AbbVie, AstraZeneca, Amgen, Bayer, Bristol-Myers Squibb, Dalcor, GlaxoSmithKline, Merck, Novartis, Resverlogix, Stealth and Theracos. In addition, his travel and accommodation costs for attendance at meetings related to some of the clinical trials have been funded by these sponsors. JJVM’s employer has also paid for his attendance at advisory boards organised by Novartis and Sanofi-Aventis.